Researchers used a national database of medical and pharmacy claims for commercially insured and Medicare Advantage beneficiaries in the U.S. The study examined 48 million individuals with any period of insurance coverage between Jan. 1, 2007 and Dec. 31, 2016.
The study shows annual opioid use prevalence was 14 percent for commercial beneficiaries, 26 percent for Medicare beneficiaries (65 years and older) and 52 percent for disabled Medicare beneficiaries (under 65 years of age).
Among the commercial beneficiaries quarterly prevalence of opioid use changed little, remaining at 6 percent through the study period. For Medicare beneficiaries, quarterly use prevalence ranged from 11 percent at the beginning of the study period to 14 percent at the end.
Among disabled Medicare beneficiaries both quarterly use rates (39 percent) and average daily dose (56 milligram morphine equivalents) were higher at the end of 2016 than the low points observed in 2007.
“Opioid use and average daily dose have not substantially declined from their peaks, despite increased attention to opioid abuse and awareness of their risks,” study authors concluded.
More articles on opioids:
10 opioid stories in July
Iowa’s opioid prescription rate declines
Federal judge rules opioid distribution data not meant for public eye
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
